Annemieke Aartsma-Rus is a Professor of Translational Genetics at the Department of Human Genetics at the LUMC. During her PhD research studies, she played an important role in the development of an antisense-mediated exon skipping therapy for Duchenne muscular dystrophy (2000-4). In 2007, she became group leader of the Duchenne exon skipping group, first as an Assistant Professor, in 2010 as Associate Professor and since 2015 as a full Professor. Annemieke also serves as a visiting Professor at the John Walton Muscular Dystrophy Research Center at the Institute of Genetic Medicine at Newcastle University (UK). In 2014, Annemieke was accepted in the Jonge Akademie (the junior section of the Dutch Royal Academy of Sciences, consisting of the 50 most prominent scientists of under 45). Presently, she serves in the scientific advisory boards of ProQR, MirRx Therapeutics and Philae Pharmaceuticals.